ActiveMax® Human VEGF121 (VE1-H4213) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 147 (Accession # NP_001020541).
Predicted N-terminus: Ala 27
This protein carries no "tag".
The protein has a calculated MW of 14 kDa (monomer). As a result of glycosylation, The protein migrates as 19 kDa and 20kDa under reducing (R) condition and 40-45 kDa (homodimer) under non-reducing (NR) condition on SDS-PAGE gel.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Human VEGF121 on SDS-PAGE under reducing (R) and no-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of ActiveMax® Human VEGF121(Cat.# VE1-H4213) was greater than 90% as determined by SEC-HPLC.
Immobilized ActiveMax® Human VEGF121 (Catalog # VE1-H4213) at 2 μg/mL can bind Human VEGF R2, Strep Tag (Catalog # KDR-H5280) with a linear range of 0.15-2.5 μg/mL.
Authors: Stafford RL et al.
Journal: Protein Engineering, Design and Selection 2014
Application: SPR(Biacore T200)
Vascular endothelial growth factor (VEGF) is also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 is the only form that lacks a basic heparinbinding region and is freely diffusible. Mouse embryos expressing only the corresponding isoform (VEGF120) do not survive to term, and show defects in skeletogenesis. Human VEGF121 shares 87% aa sequence identity with corresponding regions of mouse and rat, 93% with feline, equine and bovine, and 91%, 95% and 96% with ovine, canine and porcine VEGF, respectively. VEGF121 induces the proliferation of lymphatic endothelial cells. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.